+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: TM4 cell lysate, Primary antibody: P02561(MIER1 Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02561(MIER1 Antibody) at dilution 1/140. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P02561(MIER1 Antibody) at dilution 1/140. (Original magnification: ×200)    

  
  

MIER1 (Mesoderm Induction Early Response 1) is a transcriptional regulator encoded by the *MIER1* gene, initially identified for its role in mesoderm induction during early embryonic development. It functions as a chromatin-modifying enzyme, interacting with histone deacetylases (HDACs) and other co-repressors to regulate gene expression by altering chromatin structure. MIER1 is involved in critical cellular processes, including proliferation, differentiation, and apoptosis, and has been implicated in both developmental pathways and disease states, particularly cancer.

MIER1 antibodies are immunological tools designed to detect and study the MIER1 protein in various experimental settings. These antibodies are essential for elucidating MIER1's expression patterns, subcellular localization, and interactions with partner proteins. Research has shown that MIER1 exhibits dual roles in cancer, acting as a tumor suppressor or promoter depending on cellular context. For example, reduced MIER1 expression correlates with poor prognosis in breast and colorectal cancers, while its overexpression may drive aggressiveness in other malignancies. Antibodies against MIER1 enable techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to validate these findings in clinical samples or cell models.

Commercially available MIER1 antibodies are typically developed in hosts like rabbits or mice, targeting specific epitopes or post-translational modification sites. Their applications span basic research to biomarker discovery, aiding in understanding MIER1's regulatory mechanisms and potential therapeutic targeting. Validation of antibody specificity remains crucial due to MIER1's structural homology with other family members (e.g., MIER2) and splice variants.